Use of a population-based survey to determine incidence of AIDS-defining opportunistic illnesses among HIV-positive persons receiving medical care in the United States

Patrick S Sullivan¹ , Maxine Denniston¹ , AD McNaghten¹ , Susan E Buskin² , Stephanie T Broyles³ and Eve D Mokotoff⁴

¹Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, 1600 Clifton Road NE, MS E46, Atlanta GA 30333, USA

²Public Health – Seattle & King County, 400 Yesler Way, 3rd Floor, SeattleWA 98104, USA

³Louisiana Department of Public Health, 2021 Lakeshore Dr. Ste 210, New Orleans LA 70122, USA

⁴Michigan Department of Community Health, 1151 Taylor, Rm 211B Herman Kiefer Health Complex, Detroit MI 48202, USA

author email corresponding author email

AIDS Research and Therapy 2007, 4:17doi:10.1186/1742-6405-4-17


Published:	12 September 2007

Abstract

Background

Diagnosis of an opportunistic illness (OI) in a person with HIV infection is a sentinel event, indicating opportunities for improving diagnosis of HIV infection and secondary prevention efforts. In the past, rates of OIs in the United States have been calculated in observational cohorts, which may have limited representativeness.

Methods

We used data from a 1998 population-based survey of persons in care for HIV infection to demonstrate the utility of population-based survey data for the calculation of OI rates, with inference to populations in care for HIV infection in three geographic areas: King County Washington, selected health districts in Louisiana, and the state of Michigan.

Results

The overall OI rate was 13.8 per 100 persons with HIV infection in care during 1998 (95% CI, 10.2–17.3). In 1998, an estimated 11.3% of all persons with HIV in care in these areas had at least one OI diagnosis (CI, 8.8–13.9). The most commonly diagnosed OIs were Pneumocystis jiroveci pneumonia (PCP) (annual incidence 2.4 per 100 persons, CI 1.0–3.8) and cytomegalovirus retinitis (annual incidence 2.4 per 100 persons, CI 1.0–3.7). OI diagnosis rates were higher in Michigan than in the other two geographic areas, and were different among patients who were white, black and of other races, but were not different by sex or history of injection drug use.

Conclusion

Data from population-based surveys – and, in the coming years, clinical outcomes surveillance systems in the United States – can be used to calculate OI rates with improved generalizability, and such rates should be used in the future as a meaningful indicator of clinical outcomes in persons with HIV infection in care.